Fengbi Biotech’s First Quarter Report of 2026
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
Securities code: 603334 Securities abbreviation: Fengbei Biotechnology
Suzhou Fengbei Biotechnology Co., Ltd.
first quarter report
2026
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder
The company's board of directors, directors and senior managers guarantee that the contents of the quarterly report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) guarantee that the financial information in the quarterly report is true, accurate and complete.
Are the first quarter financial statements audited?
□Yes √No
1. Main financial data
(1) Main accounting data and financial indicators
Unit: Yuan Currency: RMB
Items during this reporting period compared with the same period last year This reporting period compared with the same period last year
Increase or decrease (%) operating income 1,108,730,173.16 665,694,662.72 66.55Total profit 45,841,698.02 39,627,242.18 15.68Net profit attributable to shareholders of listed companies
40,879,056.33 36,673,255.11 11.47 profit
Deductions attributable to shareholders of listed companies
34,220,007.78 36,531,308.18 -6.33 Net profit from non-recurring gains and losses
Net cash flow from operating activities
55,350,580.82 -59,725,139.04 N/A
1/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
Basic earnings per share (yuan/share) 0.28 0.34 -17.65 Diluted earnings per share (yuan/share) 0.28 0.34 -17.65 Weighted average return on net assets (%) 2.38 4.73 A decrease of 2.35 percentage points at the end of this reporting period compared with the previous year at the end of this reporting period at the end of the previous year
Final increase or decrease (%) Total assets 2,166,450,656.49 2,225,344,331.56 -2.65 All assets attributable to shareholders of listed companies
1,739,284,730.78 1,697,778,510.26 2.44 shareholders’ rights and interests
(2) Non-recurring profit and loss items and amounts
√Applicable □Not applicable
Unit: Yuan Currency: RMB
Non-recurring gains and losses items Amount for the current period Description of gains and losses from disposal of non-current assets, including accrued asset deductions
Offset portion of value provision
Government subsidies are included in the current profit and loss, but are not related to the company’s normal operations.
Closely related to business operations, in compliance with national policies and regulations, and in accordance with
7,450,530.00 determined standard enjoyment, which will have a continuous impact on the company’s profit and loss
Except for government subsidies
Except for effective hedging related to the company’s normal business operations
In addition to business, non-financial enterprises hold financial assets and financial liabilities
261,689.70 Gains and losses from changes in fair value of bonds and disposal financing
Profit and loss arising from assets and financial liabilities
The proportion of funds collected from non-financial enterprises included in the current profit and loss
fees
Gains and losses from entrusting others to invest or manage assets
Profit and loss from external entrusted loans
Due to force majeure factors, such as natural disasters
Loss of various assets
Reversal of impairment provision for accounts receivable that has been individually tested for impairment
The enterprise obtains investment from subsidiaries, associates and joint ventures
If the capital cost is less than when the investment is obtained, the invested unit shall enjoy
Gains from identifying the fair value of net assets
The balance sheet of subsidiaries resulting from business combinations under common control from the beginning to the end of the period
Net profit and loss for the current period on the date of merger
Gains and losses on non-monetary asset exchanges
Debt restructuring gains and losses
An incident that occurs because the relevant business activities of the enterprise are no longer sustainable.
Sexual expenses, such as expenses for placement of employees, etc.
2/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
Due to adjustments in taxation, accounting and other laws and regulations, the current period's losses
one-time impact
The shares recognized in one go due to the cancellation or modification of the equity incentive plan
payment fee
For cash-settled share-based payment, on the vesting date
After that, losses arising from changes in the fair value of employee compensation payable
benefit
Investment properties that adopt the fair value model for subsequent measurement
Gains and losses arising from changes in fair value of real estate
Gains from transactions where the transaction price appears to be unfair
Contingencies unrelated to the company's normal business operations arise
Profit and loss
Custody fee income from entrusted operations
Other non-operating income and expenses other than the above items 176,094.08
Other profit and loss items that meet the definition of non-recurring profits and losses
Less: Income tax impact 1,229,265.17
Impact on minority shareholders’ equity (after tax) 0.06
Total 6,659,048.55
If the company determines items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and is significant in amount, and if it defines the non-recurring gain or loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as recurring gains and losses, the reasons should be explained. □Applicable √Not applicable
(3) Changes in main accounting data and financial indicators and reasons
√Applicable □Not applicable
Project name Change ratio (%) Main reasons
Operating income 66.55 Bio-based material sales growth
2. Shareholder information
(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders. Table unit: shares
Preference shareholders whose voting rights were restored at the end of the reporting period Total number of ordinary shareholders at the end of the reporting period 17,894 0 Total number (if any)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Pledge and mark shareholding
Name of the shareholder who holds the sales restriction clause, nature of the shareholder, number of shares held, proportion
Number of shares Number of shares (%)
status quantity
3/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
Plain Domestic natural person 64,321,607 44.82 64,321,607 None 0Zhangjiagang Free Trade Zone Zhonghe Business Consulting
Others 18,222,393 12.70 18,222,393 None 0 Partnership (limited partnership)
Zhangjiagang Free Trade Zone Fubei Huiying Enterprise
Others 9,344,011 6.51 9,344,011 None 0 Management partnership (limited partnership)
Jiangsu Binquan Yida Zhanxin Venture Capital
Others 5,743,001 4.00 5,743,001 None 0 Partnership (limited partnership)
Shanghai Zhishi Enterprise Management Consulting Partnership
Others 5,289,606 3.69 5,289,606 None 0 Enterprise (limited partnership)
Yangzhong Hi-tech Investment Yida Venture Capital Fund
Others 2,871,501 2.00 2,871,501 None 0 Partnership (limited partnership)
Haifutong Fund-CITIC Bank-Haifutong Fund
Futong Fengbei Biotech employees participate in the main board Others 2,041,649 1.42 2,041,649 None 0 Strategic placement collective asset management plan
Fubai Huiying No. 2, Zhangjiagang Free Trade Zone
Corporate management partnership (limited partnership, other 1,807,881 1.26 1,807,881 None 0 partnership)
China Insurance Investment Co., Ltd.-China
National Insurance Investment Fund (Limited Co., Ltd. Others 1,633,319 1.14 1,633,319 None 0 units)
Shanghai Ruiyi Investment Development Center (with
Limited partnership) - Ruiyi Investment Fixed Increase Others 804,948 0.56 0 None 0 Select 10-phase private equity investment fund
Shareholding status of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing)
Type and quantity of shares
Name of shareholder Number of shares held without selling restrictions
Type of shares Quantity Shanghai Ruiyi Investment Development Center (with
Limited partnership) - Ruiyi Investment Fixed Increase 804,948 RMB ordinary shares 804,948 Select ten-phase private securities investment fund
CITIC Securities Asset Management (Hong Kong)
797,974 RMB ordinary shares 797,974 Co., Ltd. - client funds
China Construction Bank Corporation
- Cathay Haitong Jundexin has held 733,670 RMB ordinary shares for two years and 733,670 hybrid securities investment funds.
Xu Jialu 616,200 RMB ordinary shares 616,200 Shanghai Ruiyi Investment Development Center (with
Limited partnership) - Ruiyi Investment Panshan 2 551,243 RMB ordinary shares 551,243 securities private equity investment funds
Wang Kongbo 414,700 RMB ordinary shares 414,700 Zeng Zhimin 354,600 RMB ordinary shares 354,600 Yu Zhitao 298,700 RMB ordinary shares 298,700
4/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
Shanghai Ruiyi Investment Development Center (with
Limited partnership) - Ruiyi Investment Lanyue San 297,500 RMB ordinary shares 297,500 private securities investment funds
Jiangyin Hualan Mechanical and Electrical Technology Co., Ltd. 279,538 RMB ordinary shares 279,538 The company's controlling shareholder and actual controller Pingyuan serves as the executive partner of Zhangjiagang Free Trade Zone Zhonghe Business Consulting Partnership (Limited Partnership) and Zhangjiagang Free Trade Zone Fubei Huiying Enterprise Management Partnership (Limited Partnership); the above-mentioned shareholders of Jiangsu Banquan Yida Zhanxin Venture Capital are related or in the same industry
Partnership (limited partnership) and Yangzhong Hi-tech Investment Yida Venture Capital Fund Partnership (explanation with changes
Limited partnership) private equity fund managers are all Nanjing Yida Equity Investment Management Enterprise (limited partnership). In addition, the company does not know whether there is any related relationship or concerted action relationship among the other shareholders mentioned above.
Shanghai Ruiyi Investment Development Center (Limited Partnership) - Ruiyi Investment Fixed-Issuance Selected Ten-Phase Private Securities Investment Fund holds 804,948 shares, of which 804,948 shares are held through investor credit securities accounts; Xu Jialu holds 616,200 shares, Among them, 616,200 shares are held through investor credit securities accounts; Shanghai Ruiyi Investment Development Center (Limited Partnership)-Ruiyi Investment Panshan Phase II Securities Private Equity Investment Fund holds 551,243 shares, of which the top 10 shareholders and the top 10 unlimited
Holds 551,243 shares through investor credit securities account; Wang Kongbo holds 414,700 shares, and the selling shareholder participates in margin financing, securities lending and refinancing
Among them, 414,700 shares are held through investor credit securities accounts; description of Zeng Zhimin’s holding business (if any)
354,600 shares, of which 84,600 shares are held through ordinary securities accounts and 270,000 shares are held through investor credit securities accounts; Yu Zhitao holds 298,700 shares, of which 298,700 shares are held through investor credit securities accounts; Jiangyin Hualan Mechanical and Electrical Technology Co., Ltd. holds 279,538 shares, of which 279,538 shares are held through investor credit securities accounts.
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
□Applicable √Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□Applicable √Not applicable
3. Other reminders
Investors need to be reminded of other important information regarding the company’s operations during the reporting period.
□Applicable √Not applicable
4. Quarterly Financial Statements
(1) Types of audit opinions
□Applicable √Not applicable
5/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
(2) Financial statements
Consolidated Balance Sheet
March 31, 2026
Prepared by: Suzhou Fengbei Biotechnology Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Item March 31, 2026 Current assets on December 31, 2025:
Monetary funds 662,577,172.33 567,157,391.04 Settlement reserves
Loan funds
Trading financial assets 130,004,974.20 300,141,723.04 Derivative financial assets
Notes receivable 44,691,723.42 59,241,556.25 Accounts receivable 146,040,276.85 172,585,957.63 Receivables financing 45,334,654.81 12,862,336.23 Prepayments 145,028,979.68 43,911,971.98 premiums receivable
Reinsurance accounts receivable
Receivable reinsurance contract reserves
Other receivables 13,026,820.00 12,366,438.25 Including: interest receivable
Dividends receivable
Buy financial assets under resale agreements
Inventory 453,658,476.47 522,601,983.74 Including: data resources
Contract assets 4,505,898.61 4,505,898.61 Assets held for sale
Non-current assets due within one year
Other current assets 25,108,419.90 31,907,618.43
Total current assets 1,669,977,396.27 1,727,282,875.20 Non-current assets:
Grant loans and advances
debt investment
Other debt investments
long-term receivables
long term equity investment
Other equity instrument investments
Other non-current financial assets
investment real estate
Fixed assets 386,309,347.22 389,868,420.82 Construction in progress 26,587,850.31 25,201,303.41
6/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
productive biological assets
oil and gas assets
Right-of-use assets 1,575,533.67 1,811,863.71 Intangible assets 62,770,932.32 63,066,364.50 Including: data resources
development expenditure
Among them: data resources
Goodwill 17,176.80 17,176.80 Long-term deferred expenses 1,668,353.94 1,622,014.62 Deferred income tax assets 11,457,108.36 11,655,955.77 Other non-current assets 6,086,957.60 4,818,356.73 Total non-current assets 496,473,260.22 498,061,456.36
Total assets 2,166,450,656.49 2,225,344,331.56 Current liabilities:
Short-term borrowings 122,273,641.03 222,713,829.84 Borrowings from the central bank
borrowing funds
Trading financial liabilities 305,770.33 258,500.64 Derivative financial liabilities
Notes payable 38,082,701.61 55,314,977.51 Accounts payable 120,626,823.03 112,977,617.18 Advance payments
Contract liabilities 83,593,181.08 51,076,712.73 Financial assets sold and repurchased
Taking deposits and placing deposits with other banks
Agent for buying and selling securities
Agent underwriting securities funds
Employee benefits payable 6,393,869.82 14,760,653.11 Taxes payable 21,847,595.51 19,080,417.25 Other payables 1,721,774.57 1,941,071.68 Including: interest payable
Dividends payable
Handling fees and commissions payable
Reinsurance accounts payable
Liabilities held for sale
Non-current liabilities due within one year 1,756,026.39 6,141,964.32 Other current liabilities 17,462,677.23 7,550,145.16
Total current liabilities 414,064,060.60 491,815,889.42 Non-current liabilities:
insurance contract reserves
Long-term borrowings 22,440,000.00 Bonds payable
7/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
Among them: preferred shares
perpetual bond
Lease liabilities 490,141.11 486,059.00 Long-term payables
Long-term employee benefits payable
Estimated liabilities
Deferred income 10,240,579.57 10,484,706.38 Deferred income tax liabilities 372,368.53 372,843.26 Other non-current liabilities
Total non-current liabilities 11,103,089.21 33,783,608.64
Total liabilities 425,167,149.81 525,599,498.06 Owners’ equity (or shareholders’ equity):
Paid-in capital (or share capital) 143,500,000.00 143,500,000.00 Other equity instruments
Among them: preferred shares
perpetual bond
Capital reserve 955,868,164.13 955,240,999.94 Less: treasury shares
other comprehensive income
special reserve
Surplus reserve 37,647,819.58 37,647,819.58 General risk reserve
Undistributed profits 602,268,747.07 561,389,690.74 Attributable to the owner’s equity of the parent company (or
1,739,284,730.78 1,697,778,510.26 shareholders’ equity) total
Minority shareholders’ equity 1,998,775.90 1,966,323.24Owner’s equity (or shareholders’ equity)
1,741,283,506.68 1,699,744,833.50 total
Liabilities and owners' equity (or shares
2,166,450,656.49 2,225,344,331.56 East equity) total
Person in charge of the company: Pingyuan Person in charge of accounting work: Gu Yazhou Accounting department person in charge: Shen Minjuan
consolidated income statement
January-March 2026
Prepared by: Suzhou Fengbei Biotechnology Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Project First Quarter of 2026 First Quarter of 2025
- Total operating income 1,108,730,173.16 665,694,662.72 Including: operating income 1,108,730,173.16 665,694,662.72 Interest income
8/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
Premiums earned
Fee and commission income
- Total operating costs 1,076,029,075.77 624,358,737.52 Including: operating costs 1,041,954,277.29 599,240,239.77 Interest expenses
Handling fees and commission expenses
surrender deposit
Net compensation expenses
Net withdrawal of insurance liability reserves
policy dividend payout
Reinsurance cost
Taxes and surcharges 2,621,372.69 1,268,575.81 Sales expenses 4,070,055.73 3,921,417.60 Management expenses 9,432,960.11 7,459,097.49 Research and development expenses 14,253,129.99 12,139,745.40 Financial expenses 3,697,279.96 329,661.45 Including: interest expenses 637,208.50 1,447,270.16
Interest income 393,437.45 137,296.76 plus: other income 11,569,881.62 5,226,569.13 Investment income (losses are listed with "-") 445,708.23 -196,839.38 Including: losses to associates and joint ventures
investment income
Financial assets measured at amortized cost
Derecognition of revenue
Exchange gains (losses are listed with "-")
Net exposure hedging income (losses are filled in with "-"
column)
Gains from changes in fair value (losses are marked with a “-”
-184,018.53 77,267.54 fill in the column)
Credit impairment losses (losses are filled in with "-"
1,323,156.85 -6,606,739.27 columns)
Asset impairment losses (losses are filled in with "-"
161,966.54 -216,106.45 columns)
Asset disposal income (losses are filled in with "-"
806.05 column)
Operating profit (losses are listed with "-") 46,017,792.10 39,620,882.82 Plus: non-operating income 5,863.56 6,509.94 Less: non-operating expenses 181,957.64 150.58
Total profits (total losses are listed with "-") 45,841,698.02 39,627,242.18 Less: income tax expenses 4,930,189.03 2,953,987.07
Net profit (net loss is listed with "-") 40,911,508.99 36,673,255.11
(1) Classification by business continuity
9/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
- Net profit from continuing operations (net loss is marked with "-"
40,911,508.99 36,673,255.11 fill in the column)
- Net profit from discontinued operations (net loss is listed with "-")
(2) Classification according to ownership ownership
- Net profit attributable to shareholders of the parent company (net
40,879,056.33 36,673,255.11 Losses are listed with a “-” sign)
- Profit and loss of minority shareholders (net loss is filled in with "-"
32,452.66 columns)
6. Net amount of other comprehensive income after tax
(1) Net after-tax amount of other comprehensive income attributable to owners of the parent company
- Other comprehensive income that cannot be reclassified into profit or loss
(1) Remeasurement of changes in defined benefit plan (2) Other comprehensive income that cannot be transferred to profit or loss under the equity method
(3) Changes in the fair value of other equity instrument investments (4) Changes in the fair value of the company’s own credit risk
- Other comprehensive income that will be reclassified into profit and loss (1) Other comprehensive income that can be transferred to profit and loss under the equity method
(2) Changes in fair value of other debt investments
(3) The amount of financial assets reclassified and included in other comprehensive income
(4) Credit impairment provisions for other debt investments
(5) Cash flow hedging reserve
(6) Translation differences of foreign currency financial statements
(7) Others
(2) Net after-tax amount of other comprehensive income attributable to minority shareholders
- Total comprehensive income 40,911,508.99 36,673,255.11
(1) Comprehensive income attributable to owners of the parent company
40,879,056.33 36,673,255.11 Total profit
(2) Total comprehensive income attributable to minority shareholders
32,452.66 amount
8. Earnings per share:
(1) Basic earnings per share (yuan/share) 0.28 0.34
(2) Diluted earnings per share (yuan/share) 0.28 0.34
If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0 yuan, and the net profit realized by the merged party in the previous period is: 0 yuan.
Person in charge of the company: Pingyuan Person in charge of accounting work: Gu Yazhou Accounting department person in charge: Shen Minjuan
10/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
Consolidated Cash Flow Statement
January-March 2026
Prepared by: Suzhou Fengbei Biotechnology Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Project First Quarter of 2026 First Quarter of 2025
1. Cash flow generated from operating activities:
Cash received from sales of goods and provision of services 1,351,668,734.43 633,382,564.57 Net increase in customer deposits and interbank deposits
Um
Net increase in borrowing from the central bank
Net increase in borrowing funds from other financial institutions
Um
Cash received from premiums from the original insurance contract
Net cash received from reinsurance business
Net increase in policyholders’ savings and investment funds
Cash collected from interest, fees and commissions
Net increase in borrowing funds
Net increase in repurchase business funds
Net cash received from buying and selling securities on behalf of agents
Tax returns received 3,860,066.99 9,482,409.19 Other cash received related to operating activities 2,334,932.61 2,623,319.79
Subtotal of cash inflows from operating activities 1,357,863,734.03 645,488,293.55 Cash paid for purchasing goods and receiving services 1,240,601,086.72 651,652,319.44 Net increase in customer loans and advances
Net increase in deposits with central banks and inter-banks
Um
Cash used to pay compensation from the original insurance contract
Net increase in lending funds
Cash payments for interest, fees and commissions
Cash payment for policy dividends
Cash paid to and for employees 23,726,482.80 18,774,315.01 Various taxes and fees paid 27,479,618.18 11,790,277.65 Cash paid for other operating activities 10,705,965.51 22,996,520.49 Subtotal of cash outflows from operating activities 1,302,513,153.21 705,213,432.59 Net cash flow generated from operating activities
55,350,580.82 -59,725,139.04 amount
2. Cash flow generated from investing activities:
Cash received from recovery of investment 270,000,000.00
Cash received from investment income 747,328.77
Disposal of fixed assets, intangible assets and other
4,500.00 Net cash received from long-term assets
11/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
Received from disposal of subsidiaries and other business units
net cash
Other cash received related to investing activities 279,327.08
Subtotal of cash inflows from investing activities 271,026,655.85 4,500.00 Purchase and construction of fixed assets, intangible assets and others
10,737,835.91 6,639,904.63 Cash paid for long-term assets
Cash paid for investment 100,000,000.00
Net increase in mortgage loans
Obtain payment from subsidiaries and other business units
net cash
Cash payments related to other investment activities 223,950.00
Subtotal of cash outflows from investing activities 110,961,785.91 6,639,904.63 Net cash flows from investing activities
160,064,869.94 -6,635,404.63 amount
3. Cash flow generated from financing activities:
Absorbing cash received from investments
Among them: subsidiaries absorb investment from minority shareholders
cash received
Cash received from borrowings 20,500,000.00 129,500,000.00 Cash received from other financing activities
Subtotal of cash inflows from financing activities 20,500,000.00 129,500,000.00 Cash paid to repay debts 130,400,000.00 105,100,000.00 Distribution of dividends, profits or interest payments
1,440,574.75 2,322,627.38 in cash
Including: Payments made by subsidiaries to minority shareholders
dividends, profits
Payment of other cash related to financing activities 600,000.00 Subtotal cash outflow from financing activities 131,840,574.75 108,022,627.38 Net cash flow generated from financing activities
-111,340,574.75 21,477,372.62 amount
4. Exchange rate changes on cash and cash equivalents
-2,392,588.47 Impact of 1,255,613.29
Net increase in cash and cash equivalents 101,682,287.54 -43,627,557.76 plus: opening balance of cash and cash equivalents 547,191,339.25 150,791,166.09
Balance of cash and cash equivalents at the end of the period 648,873,626.79 107,163,608.33
Person in charge of the company: Pingyuan Person in charge of accounting work: Gu Yazhou Accounting department person in charge: Shen Minjuan
12/13
Suzhou Fengbei Biotechnology Co., Ltd. 2026 First Quarter Report
(3) The first implementation of new accounting standards or standard interpretations starting from 2026 will involve adjustments to the financial statements at the beginning of the year of first implementation □ Applicable √ Not applicable
Announcement hereby
Board of Directors of Suzhou Fengbei Biotechnology Co., Ltd. April 28, 2026
13/13